Shifting from the development stage to the sales stage

In the oriental medicine and natural products field, support that had previously remained at the level of research or prototype production is moving toward actual sales and distribution. The Jecheon Foundation of Korean Medicine and Natural Products Industry Promotion is seeking to divide roles with private companies and connect support through the stages after product development, while the trend of reviewing distribution channels including Olive Young and the $3.89 million export agreement show a view that commercialization can only succeed when regional industries secure market channels first.

This change emerged from the reality that region-based industries find it difficult to grow on technological capability or raw-material competitiveness alone. Since revenue potential arises only when production, distribution, consulting, and exhibitions are tied together as one process, support agencies have now entered a stage where they must demonstrate results through market entry rates rather than the number of development projects.

Accelerating the consumer-product conversion of traditional materials

On the ground, traditional Korean medicine materials and practices are being reconfigured into consumer goods and services beyond the treatment room. A silicone home-wellness self-care cup created by a student startup team has gone on to secure official placement at Mega High Pharmacy, while a skin-treatment model emphasizing collaboration between Western and Korean medicine is preparing to open a U.S. branch, expanding the boundary between healthcare and wellness.

This trend is appearing because consumers want not only treatment to cure illness, but also an integrated experience that combines prevention, management, appearance improvement, and self-care. It means that if Korean medicine is to expand its influence in the modern market, it has become increasingly important to turn traditional knowledge into explainable products and services that can be purchased repeatedly.

A phase in which research institutions and regulation are changing at the same time

The expansion of Korean medicine is proceeding not only in the sales field but also simultaneously in research and institutions. The Korea Institute of Oriental Medicine has opened a Korean Medicine Brain and Neuroscience Research Center and is promoting an AI Korean Medicine Hub, while in the National Assembly, pressure is growing to redesign education, licensing, and research systems as debate continues over medical unification.

These developments are the result of overlapping challenges such as population aging, an increase in brain disorders, and digital transformation, all of which are difficult to address through existing methods alone. However, for more advanced research and institutional integration discussions to lead to real trust, they must be followed by efforts to reduce professional turf conflicts and show more clearly the processes of scientific verification and data accumulation.

Growing demands for cost and quality control alongside growth

Market expansion does not automatically lead to greater trust in the industry. Medical expenses for minor injury patients under auto insurance rose from 1.1499 trillion won in 2021 to 1.5129 trillion won last year, while controversy over large-scale advance preparation at external herbal dispensaries and the Mizulan trademark dispute together exposed weaknesses in cost expansion and in quality and distribution management.

This means that the larger a role the Korean medicine industry takes within the institutional system, the more it will be required to meet the same level of verification and oversight. Going forward, competitiveness is likely to depend less on simply expanding demand and more on how well it manages the burden on insurance finances, how clearly it defines the boundaries of products and compounding, and how effectively it secures consumer trust.